Related Experiment Video For Biomarkers
Updated: Oct 1, 2025
Cell-Free DNA Integrity Analysis in Urine Samples
Published on: January 5, 2017
Improved urine DNA methylation panel for early bladder cancer detection
Qixun Fang1,2, Xu Zhang3, Qing Nie1
1Yaneng Bioscience, Co., Ltd, Shenzhen, 518100, China.
Background:
Bladder cancer is one of the most common malignancies but the corresponding diagnostic methods are either invasive or limited in specificity and/or sensitivity. This study aimed to develop a urine-based methylation panel for bladder cancer detection by improving published panels and validate performance of the new panel with clinical samples.
Methods:
Related researches were reviewed and 19 potential panels were selected. RRBS was performed on a cohort with 45 samples to reassess these panels and a new panel inherited best markers was developed. The new panel was applied with qMSP platform to 33 samples from the RRBS cohort and the results were compared to those of RRBS. Lastly, another larger cohort with 207 samples was used to validate new panel performance with qMSP.
Results:
Three biomarkers (PCDH17, POU4F2 and PENK) were selected to construct a new panel P3. P3 panel achieved 100% specificity and 71% sensitivity with RRBS in corresponding cohort and then showed a better performance of 100% specificity and 84% sensitivity with qMSP platforms in a balanced cohort. When validated with 207-sample cohort, P3 with qMSP showed a performance of 97% specificity and 87% sensitivity which was modestly improved compared to the panels it derided from.
Conclusions:
Overall, the P3 panel achieved relatively high sensitivity and accuracy in bladder cancer detection.
